ReviewMedComm2026
Organ Transplantation: Current Status, Challenges, and Future Prospects.
Review in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Organization from cell to tissue derived delivery systems for immunotherapy.Materials today. Bio · 2026Article
- Human iPSC-derived 3D cardiac models for cardiomyopathies: organoids, spheroids, and engineered heart tissues as translational platforms.Stem cells (Dayton, Ohio) · 2026Review
- CRISPR-based ex vivo gene editing of donor organs.Nature reviews bioengineering · 2026Article
- Tissue-resident memory T cells in organ transplantation: implications for immune homeostasis and graft outcomes.Inflammation and regeneration · 2026Review
- Transforming organ donation and transplantation: challenges, innovations, and future directions.Frontiers in transplantation · 2026Review
- Knowledge and attitude of Malaysian university students towards regenerative medicine therapy and their clinical implications: a cross-sectional study.Frontiers in genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Organ transplantation has progressed from a life-saving surgical intervention to a multidisciplinary field integrating immunology, bioengineering, and data science. Despite major advances in donor management, perioperative care, and immunosuppression, long-term graft survival remains limited due to chronic rejection, infection, and organ scarcity. Recent breakthroughs in organ preservation, particularly in hypothermic and normothermic machine perfusion, have enabled real-time graft assessment, metabolic reconditioning, and localized therapeutic delivery. Emerging precision immunomodulation strategies, including regulatory T-cell therapy, gene-edited cellular platforms, tolerogenic dendritic cells, and biomarker-guided minimization, are reshaping alloimmune control toward durable tolerance. Innovations in xenotransplantation, multigene-edited donor animals, and tissue biofabrication offer potential solutions to structural organ shortages, although they are accompanied by regulatory and ethical challenges. Artificial intelligence further enhances donor-recipient matching, risk prediction, and personalized immunosuppressive management. This review synthesizes advances in preservation technologies, immune engineering, cellular tolerance induction, artificial intelligence-driven decision support, and xenotransplantation and provides a comprehensive overview of the evolving transplant landscape. By integrating mechanistic insights into translational progress, we outline future pathways for regenerative, immune-educational, and precision organ medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.